VectorY Therapeutics Appoints Jessica Atkinson as Chief Business Officer
VectorY Therapeutics, a biotechnology company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, today announced the appointment of Jessica Atkinson as Chief Business Officer (CBO). In this newly created role, Atkinson will partner with the Chief Executive Officer and management team to develop long-term business and commercial strategies that support company growth, and will also drive strategic partnerships.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250527171431/en/
Jessica Atkinson, New CBO at VectorY Therapeutics
Atkinson brings over two decades of business development and commercialization experience across biopharmaceutical companies and innovative startups. She has held leadership roles at ImmuneID, Glympse Bio, and Foundation Medicine, where she spearheaded strategic partnerships and corporate strategy initiatives. She also held roles of increasing responsibility over seven years in the U.S. commercial organization of Merck & Co. Most recently, Atkinson served as a fractional CBO or strategic advisor to multiple early-stage biotech companies through her consulting firm, TwoStep Advisors.
'I'm delighted to welcome Jessica to VectorY,' said Jim Scibetta, chief executive officer of VectorY Therapeutics. 'Her proven expertise in shaping strategy and driving successful transactions across all stages of drug development will be invaluable as we advance our pipeline and pursue new opportunities. Jessica's collaborative approach and strategic vision make her an ideal addition to our leadership team.'
'VectorY's pioneering approach to developing vectorized antibody therapeutics holds immense promise for patients with neurodegenerative diseases,' said Atkinson. 'I look forward to working closely with the management and research teams to further develop our corporate strategy and to create transformative alliances and business collaborations that support the company's mission and long-term success.'
Atkinson holds a Bachelor of Science degree in Molecular Biology from the University of Texas, Austin. She has been an advocate for encouraging women to pursue careers in science and volunteers with Mass General Cancer Center's Peer Mentoring program that offers patients and family members the opportunity to speak by telephone one-to-one with an experienced patient.
About VectorY
VectorY is on a mission to provide people with neurodegenerative diseases a longer, better life by creating transformative vectorized antibody treatments. Our platform combines the promise of precise therapeutic antibodies with one-time AAV-based delivery to the CNS. Unique in-house expertise in antibodies, AAV vectors, protein degradation, manufacturing and neuroscience drives the rapid development of much needed disease-modifying therapies for neurodegenerative diseases such as ALS and Huntington's disease. For more information, see www.vectorytx.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250527171431/en/
CONTACT: VectorY Therapeutics B.V.
E-mail:[email protected]
Tel: +31 20 226 8020
Vigo Consulting (Media)
Melanie Toyne-Sewell / Rozi Morris
E-mail:[email protected]
Tel: +44 207 390 0237 / +44 20 7390 0231
KEYWORD: MASSACHUSETTS EUROPE UNITED STATES NETHERLANDS NORTH AMERICA
INDUSTRY KEYWORD: SCIENCE NEUROLOGY OTHER SCIENCE BIOTECHNOLOGY RESEARCH PHARMACEUTICAL HEALTH CLINICAL TRIALS
SOURCE: VectorY Therapeutics
Copyright Business Wire 2025.
PUB: 05/27/2025 07:05 AM/DISC: 05/27/2025 07:05 AM
http://www.businesswire.com/news/home/20250527171431/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
Hemp on England's quick turnaround after France defeat
Boston College linebacker on how he fought to return to the game Bryce Steele is a Division 1 Linebacker who was diagnosed with cancer when he was just 17 years old. He's battled back more than once to get back onto the field and is now looking forward to his last season with the Boston College Eagles.
Yahoo
5 hours ago
- Yahoo
Sana Biotechnology, Inc. (SANA) Secures an Overweight Rating from Morgan Stanley
Sana Biotechnology, Inc. (NASDAQ:SANA) is among the . Morgan Stanley has assumed coverage on Sana Biotechnology, Inc. (NASDAQ:SANA) with an Overweight rating and a price target of $12.00. This optimism is totally in line with market sentiments that acknowledge the platform's potential to develop tailored therapies driven by engineered cells. The research firm's confidence underpins the recent 12-week and 6-month T1D data for what the firm calls an 'early proof point that helps validate the platform.' This means that the current price is nothing when the scale of opportunities of the company's hypoimmune platform is considered. The analysts believe that the risk/reward profile is closely tied to the upside ahead of sustained pipeline progress. While the risk may be high, the reward is even higher. A scientist working with a microscope in a laboratory, focusing on a cell of a medical experiment. The year-to-date returns of 93% delivered by Sana Biotechnology, Inc. (NASDAQ:SANA) is a testament to the company's efforts, particularly in the context of Type 1 Diabetes – a market with the potential to reach as high as $24.36 billion by 2031. Sana Biotechnology, Inc. (NASDAQ:SANA) is a Washington-based biotechnology company that uses engineered cells as medicines across the United States. The core offerings of the company include UP421, SC451, SC291, and SG299. Founded in 2018, the company has agreements with Beam Therapeutics Inc. and Harvard College. While we acknowledge the potential of SANA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
Yahoo
6 hours ago
- Yahoo
Ahold Delhaize appoints auto industry veteran as CTO
This story was originally published on CIO Dive. To receive daily news and insights, subscribe to our free daily CIO Dive newsletter. Grocery giant Ahold Delhaize appointed Jan Brecht as CTO and member of its executive committee, effective Sept. 26, the company said Thursday. Brecht will replace departing CTO Ben Wishart, who first joined the company in 2013. Brecht comes to the company after an extensive career in the auto industry, most recently serving as chief digital information officer at Nissan. Previously, Brecht served as CIO of the Mercedes-Benz and as CIO and head of global supply chain at Adidas. At Ahold Delhaize, Brecht will lead the company's technology function, overseeing enterprise tech strategy, digital innovation and cybersecurity, according to the announcement. Ahold Delhaize's CTO appointment comes amid a broader tech adoption push at the food retailer, the parent company of Giant, Stop & Shop and other grocers. "Identifying innovation solutions and leveraging the power of AI and data are both critical components that enable us to innovate for growth and efficiency," said CEO Frans Muller, during an earnings call in May. "We have made good progress on this front during the quarter, with several initiatives we believe can scale over time." In February, Ann Dozier joined Ahold Delhaize's U.S. division as its CIO. Previously the chief information and technology officer at Southern Glazer's Wine and Spirits, Dozier was brought in to lead IT operations with a focus on omnichannel for Ahold Delhaize's U.S. grocery brands. Ahold Delhaize has also been braving the effects of a November 2024 cybersecurity breach that disrupted e-commerce systems for several days and exposed the data of more than 2 million current and former employees. Other food retailers have also been sharpening technology strategies to support productivity and cost-consciousness. U.S.-based grocery chain Giant Eagle announced in June it rolled out a cloud-based warehouse management system to optimize operations. To support its membership growth plans, Walmart-owned Sam's Club is working to improve digital shopping for customers, including the migration of its app to the same platform Walmart uses. In the aftermath of a failed merger with rival grocery chain Kroger, Albertsons said it is working to bolster its data science capabilities amid a productivity and AI adoption push. Technology improvements, including a real-time comprehensive data platform, are part of a three-year cost-cutting initiative announced in January, CEO Susan Morris said in an April earnings call. Recommended Reading Geopolitics invades technology decision making Sign in to access your portfolio
